|Content Release Date: 7/19/2022
Expiration Date: 7/19/2023
Activity Type: Application-based
CE Credits: 1.00 hour
Activity Fee: Free
This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.
Vaccination is the most effective method to prevent COVID-19, and death rates worldwide are highest among people who are unvaccinated. Although the push to get Americans vaccinated against COVID-19 is ongoing, patients with compromised immune systems remain a challenge. There are roughly 7 million immunocompromised adults in the U.S., which includes those who have had organ transplants, stem cell transplants, and cancer as well as those with primary immunodeficiency and those treated with immunosuppressive medications. Newer monoclonal antibodies may be successful in preventing SARS-CoV-2 infection as an alternative to vaccination for people who cannot take a vaccine or need immediate prophylaxis before or after exposure.
This course consists of five activities (see table below) and provides 1.0 hour of continuing pharmacy education credit.
COVID-19 Prevention and Treatment Strategies for the Immunocompromised
This handout will be updated regularly throughout the year.
|CE Credits: 1.00 hours||
CE Credits: none
Engaging the Experts Podcasts
Podcast 1: Title TBD
Podcast 2: Title TBD
Podcast 3: Title TBD
|CE Credits: none|
*Please note, this activity was presented live on June 14, 2022 - you can only claim credit once for this activity; live or home study
The target audience for these educational activities is pharmacists who practice in hospitals and health systems who care for or are interested in the treatment of patients at risk for COVID-19, particularly the immunocompromised.
After participating in this CPE activity, learners should be able to:
- Describe the role of the COVID-19 vaccines in immunocompromised patients.
- Apply other COVID-19 prevention strategies in immunocompromised patients, including the role of pre-exposure prophylaxis.
- Develop a treatment plan for managing COVID-19 in the immunocompromised.
Katherine Yang, PharmD, MPH, FCSHP
Health Sciences Clinical Professor of Pharmacy
University of California, San Francisco (UCSF) School of Pharmacy
Infectious Diseases Clinical Pharmacist
UCSF Medical Center
San Francisco, California
Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics.
Monica V. Mahoney PharmD, BCPS, BCIDP, FCCP
Clinical Pharmacy Specialist, Infectious Diseases
Outpatient ID/OPAT Clinics
Beth Israel Deaconess Medical Center
Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America.
Michael Ganio, Pharm.D., M.S., BCPS, FASHP
Senior Director, Pharmacy Practice and Quality
Dr. Ganio joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS).
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
Activities can be completed in any order. Learners must review all content and complete an evaluation to receive continuing education credit for each activity that offers CE.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Provided by ASHP.
Supported by an educational grant from AstraZeneca.